Drugs / Maxitrol
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | MAXITROL | — | 1963-06-06 | fda.gov ↗ |
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06362226 | Jun 2026 | disorder of orbital region | Virginia Commonwealth University | Withdrawn | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT02792036 Background | Nov 2016 → Oct 2019 | retinoblastoma | St. Jude Children's Research Hospital | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Maxitrol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06362226 ↗ |
| Route | Topical | “is for topical ophthalmic use only” NCT02792036 ↗ |